期刊文献+

卵巢癌特异性结合肽OSTP的鉴定 被引量:2

The Specific Binding of 5-FAM-OSTP With Ovarian Cancer Cell A2780
下载PDF
导出
摘要 目的验证卵巢癌特异性结合肽(OSTP)对卵巢癌A2780细胞的特异性结合作用。方法合成OSTP并标记荧光素5-FAM。将培养的卵巢癌A2780细胞及对照组胃癌SGC7901细胞、骨肉瘤MG63细胞分别加5-FAM-OSTP孵育,荧光显微镜下观察拍照。构建卵巢癌A2780细胞荷瘤小鼠模型,尾静脉注入5-FAM-OSTP,循环1 h后进行左心室灌注,取肿瘤组织及各脏器组织,行冰冻切片,荧光显微镜下观察拍照。结果成功合成和标记5-FAM-OSTP。荧光显微镜观察显示:5-FAM-OSTP孵育后的卵巢癌A2780细胞产生明亮的黄绿色荧光,而对照组SGC7901、MG63细胞不产生荧光。裸鼠体内实验结果显示:肿瘤组织可见强荧光信号,平均荧光强度为17.656±1.980;肝组织平均荧光强度4.277±0.291;肾组织平均荧光强度4.422±0.767;其他脏器均无可见荧光信号。肿瘤组织与肝、肾组织的荧光强度间差异有显著性(P<0.05)。结论通过体内外实验证实了5-FAM-OSTP对卵巢癌A2780细胞具有特异结合作用,有望成为卵巢癌靶向化疗药物的导向肽。 Objective To verify that ovarian cancer specific targeting peptide(OSTP) is binding to ovarian cancer A2780 cell specifically which we have screened via phage display in vivo. Methods Synthesized OSTP and marked fluorescein 5-FAM. Added 5-FAM-OSTP to incubated ovarian cancer A2780 cells and gastric cancer SGC7901 cells of control group,bone sarcoma MG63 cell respectively, which were examined by fluorescence microscope. Constructed ovarian cancer A2780 cells mouse models, then 5-FAM conjugated OSTP was injected into the tail vein and allowed to circulate for I h. The mice were perfused with PBS through the left ventricle to remove unbound peptides. Tumors and control organs were excised,and frozen sections were prepared and examined by fluorescence microscopy. Results 5-FAM-OSTP was synthesized and marked successfully. The result of fluorescence showed, after the incubation of 5-FAM-OSTP ovarian cancer A2780 cells appeared bright yellow green fluorescence, while SGC7901 cell and MG63 cells did not appear fluorescence. The results of mouse in vivo targeting studies revealed, the tumor tissue had strong fluorescence signal, the average fluorescence intensity was 17. 656 ± 1. 980 ;Hepatic average fluorescence intensity was 4. 277 ±0. 291 ;Renal average fluorescence intensity was 4. 422 ± 0.767 ; Other organs were not found to have fluorescence signal. The fluorescence intensity of tumor tissue is different from liver,kidney,and the differences have statistical significance (P 〈 0.05). Conclusions 5-FAM- OSTP was tested in vivo and vitro for its binding specificity and affinity to ovarian cancer A2780 cells, OSTP maybe is the homing peptide of ovarian cancer targeted chemotherapy drugs.
出处 《中南医学科学杂志》 CAS 2013年第2期109-112,共4页 Medical Science Journal of Central South China
基金 国家自然科学基金(81101988) 湖南省教育厅课题项目(12C0350)
关键词 5-FAM—OSTP导向肽 卵巢癌A2780细胞 靶向作用 5-FAM-OSTP homing peptide ovarian cancer A2780 cell targeting effect
  • 相关文献

参考文献12

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics [ J ] CA: A Cancer Journal for Clinicians, 2009, 59 ( 4 ) 225-249.
  • 2Johnson DH. Targeted therapy in nnn-small cell lung eaneer : myth and reality [ J ]. l,ung Cancer,2003,41 ( 1 ) : 53-58.
  • 3Samar Masnmfi Moghaddam,Afshin Amini ,David L. Mor- ris, et al. Significance of vascular endothelial growth ihetor in growth and peritoneal dissemination of ovarian cancer [J]. Cancer Metastasis Rev,2012,31 ( 1 ) :143-162.
  • 4Kim A, Ueda Y, Naka T, et al. Therapeulic strategies in epithelial ovarian cancer [ J ]. Exp Clin Caeer lies, 2012,31:14.
  • 5Cannistra SA. Cancer of the ovary [ l 1. N Engl J Me(l, 2004,351 (24) :2519-2529.
  • 6俞弋,徐丛剑.卵巢癌靶向治疗的研究进展[J].国际妇产科学杂志,2012,39(2):152-157. 被引量:4
  • 7朱忠玉.噬菌体肽库技术[J].细胞生物学杂志,2000,22(1):28-31. 被引量:8
  • 8Arap W, Pasqualini R, Ruoslahti E, et al. Cancer Ireal- ment by targeted drug delive to minor vaseulature in a mouse model [-J ]. Science, 1998,279 ( 5349 ) : 377-5380.
  • 9Yang WH, Luo DF, Wang SX, el al. TMTP1 , A Nw4 Tmnor-Homing Peptids Specifically Targeling Melaslasis [ J]. Clin Cancer Res,2008,14(17) :5494-5502.
  • 10Teesalu T, Sugahara KN, Kotamraju VR, el al. C-end rule peptides mediate neuropilin-l-dependent cell, vascular, and tissue penetralion[.l]. Proc Natl Aead Sol IJ S A, 2009,06( 38 ) : 16157-16162.

二级参考文献32

  • 1Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
  • 2Spannuth WA,Sood AK,Coleman RL.Angiogenesis as a strategic target for ovarian cancer therapy[J].Nat Clin Pract Oncol,2008,5(4):194-204.
  • 3Siddiqui GK,Elmasry K,Wong Te Fong AC,et al.Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer[J].Eur J Gynaecol Oncol,2010,31(2):156-159.
  • 4Garcia AA,Hirte H,Fleming G,et al.PhaseⅡclinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer:a trial of the California,Chicago,and Princess Margaret Hospital phaseⅡconsortia[J].J Clin Oncol,2008,26(1):76-82.
  • 5Brown JV 3rd,Micha JP,Rettenmaier MA,et al.A pilot study evaluating a novel regimen comprised of carboplatin,paclitaxel,and bevacizumab for advanced-stage ovarian carcinoma[J].Int J Gynecol Cancer,2010,20(7):1132-1136.
  • 6Kobold S,Hegewisch-Becker S,Oechsle K,et al.Intraperitoneal VEGF inhibition using bevacizumab:a potential approach for the symptomatic treatment of malignant ascites?[J].Oncologist,2009,14(12):1242-1251.
  • 7Sfakianos GP,Numnum TM,Halverson CB,et al.The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy:a retrospective cohort study[J].Gynecol Oncol,2009,114(3):424-426.
  • 8Bull Phelps SL,Schorge JO,Peyton MJ,et al.Implications of EGFR inhibition in ovarian cancer cell proliferation[J].Gynecol Oncol,2008,109(3):411-417.
  • 9Heyerdahl H,Krogh C,Borrebaek J,et al.Treatment of HER2expressing breast cancer and ovarian cancer cells with alpha particleemitting 227Th-trastuzumab[J].Int J Radiat Oncol Biol Phys,2011,79(2):563-570.
  • 10Secord AA,Blessing JA,Armstrong DK,et al.PhaseⅡtrial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression:a Gynecologic Oncology Group study[J].Gynecol Oncol,2008,108(3):493-499.

共引文献10

同被引文献14

  • 1赵营,黄守松,杜佩妍.紫杉醇作为一线药物在卵巢癌化疗中的应用[J].国际医药卫生导报,2007,13(15):101-104. 被引量:5
  • 2Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60 (5):277-300.
  • 3Choi M,Fuller CD,Thomas CR,et al.Conditional survival in ovarian cancer:results from the SEER dataset 1988-2001[J].Gynecol Oncol,2008,109 (2):203-209.
  • 4Haley B,Frenkel E.Nanoparticles for drug delivery in cancer treatment[J].Urol Oncol,2008,26(1):57-64.
  • 5Cannistra SA.Cancer of the ovary[J].N Engl J Med,2004,351(24):2519-2529.
  • 6Gornstein E,Schwarz TL.The paradox of paclitaxel neurotoxicity:Mechanisms and unanswered questions[J].Neuropharmacology,2014,76:175-183.
  • 7Solary E,Mannone L,Moreau D,et al.Phase Ⅰ study of cinchonine,a multidrug resistance reversing agent,combined with the CHVP regimen in relapsed and refractory lymphroliferative syndromes[J].Leukmia,2000,14(12):2085-2094.
  • 8Straughn JM Jr,Oliver PG,Zhou T,et al.Auti-tumor activity of TRA-8 anti-death receptor(DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model[J].Gynecol Oncol,2006,101 (1):46-54.
  • 9赵霞,钟茜.卵巢癌早期筛查的争议与展望[J].西部医学,2009,21(1):1-2. 被引量:13
  • 10Wen-Jie Zhang,Yan-Xia Sui,Arun Budha,Jian-Bao Zheng,Xue-Jun Sun,Ying-Chun Hou,Thomas D Wang,Shao-Ying Lu.Affinity peptide developed by phage display selection for targeting gastric cancer[J].World Journal of Gastroenterology,2012,18(17):2053-2060. 被引量:12

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部